NCT05428033View on ClinicalTrials.gov

A Trial of Centanafadine Efficacy and Safety in Children With Attention-deficit/ Hyperactivity Disorder (ADHD)

PHASE3CompletedINTERVENTIONAL
Enrollment

574

Participants

Timeline

Start Date

July 11, 2022

Primary Completion Date

March 17, 2025

Study Completion Date

March 17, 2025

Conditions
Attention Deficit/Hyperactivity Disorder
Interventions
DRUG

centanafadine capsule

capsule

OTHER

placebo capsule

capsule

Trial Locations (1)

10012

For additional information regarding sites, contact 844-687-8522, New York

All Listed Sponsors
lead

Otsuka Pharmaceutical Development & Commercialization, Inc.

INDUSTRY